HomeADVM • NASDAQ
add
Adverum Biotechnologies Inc
Previous close
$3.14
Day range
$2.95 - $3.08
Year range
$1.78 - $8.56
Market cap
63.37M USD
Avg Volume
91.34K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 12.73M | -19.47% |
Net income | -49.19M | -61.29% |
Net profit margin | — | — |
Earnings per share | -2.34 | -162.92% |
EBITDA | -49.32M | -54.38% |
Effective tax rate | — | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 44.40M | -74.46% |
Total assets | 96.18M | -62.10% |
Total liabilities | 116.40M | 35.70% |
Total equity | -20.22M | — |
Shares outstanding | 20.98M | — |
Price to book | -3.27 | — |
Return on assets | -106.60% | — |
Return on capital | -130.10% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | -49.19M | -61.29% |
Cash from operations | -38.77M | -95.36% |
Cash from investing | 31.90M | 1,471.04% |
Cash from financing | 120.00K | 203.45% |
Net change in cash | -6.74M | 69.74% |
Free cash flow | -19.80M | -35.25% |
About
Adverum Biotechnologies, Inc., formerly known as Avalanche Biotechnologies, is a publicly traded clinical stage gene therapy company located in Redwood City, California. The company is targeting unmet medical needs for serious ocular and rare diseases, including wet age-related macular degeneration. Wikipedia
Founded
Jan 1, 2006
Headquarters
Website
Employees
155
